한국어
English
日本語
中文(简体)
Lenvatinib Capsule 4 mg (Lenvatinib Mesilate Dimethyl Sulfoxide)
5.632mg
Hard capsule · Prescription medication
Boryung Pharmaceutical Co., Ltd.
Lenvatinib Mesylate Dimethyl Sulfoxide is an active ingredient that inhibits the growth of malignant tumors.
MFDS ingredient code M285217
Lenvatinib Mesylate Dimethyl Sulfoxide belongs to the targeted chemotherapy class and is primarily used to suppress the proliferation of cancer cells. This ingredient slows the progression of cancer by blocking angiogenesis and the signaling pathways of tumor cells.
This ingredient blocks signals that promote blood vessel formation around tumor cells, thereby reducing nutrient supply to the tumor. It also inhibits the activity of specific enzymes within cancer cells, hindering cell division and growth.
Approved uses differ by product. Check each product's information for its actual use.
Lenvatinib Mesylate Dimethyl Sulfoxide is a multi-targeted anticancer agent that acts on multiple receptor tyrosine kinases simultaneously, enhancing efficacy compared to single-target therapies by blocking various pathways.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
3 total
5.632mg
Hard capsule · Prescription medication
Boryung Pharmaceutical Co., Ltd.
14.08mg
Hard capsule · Prescription medication
Boryung Pharmaceutical Co., Ltd.
16.896mg
Hard capsule · Prescription medication
Boryung Co., Ltd.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.